Chemotherapy Plus Bevacizumab Promising in Advanced TNBC
A triplet regimen including paclitaxel, capecitabine, and bevacizumab showed efficacy and safety in women with advanced triple-negative breast cancer.
This article will discuss the epidemiology, mechanisms, diagnostic methods, and management of cardiotoxicity from systemic chemotherapy used to treat breast cancer.
Condition: Breast Cancer Interventions: Combination Product: Docetaxel / Capecitabine; Combination Product: Capecitabine / Vinorelbine; Combination Product: Paclitaxel / Gemcitabine; Drug: Ribociclib; Drug: Letrozole OR Anastrozole; Drug: Goserelin Sponsor: Novartis Pharmaceuticals Not yet recruiting
Condition: Breast Cancer Interventions: Procedure: Neoadjuvant chemotherapy before surgery; Procedure: Surgery followed by adjuvant chemotherapy Sponsor: Peking Union Medical College Hospital Recruiting
ConclusionsPatients with upper gastro ‐intestinal cancers and sarcoma had the highest risk of dying from their disease. Breast cancer patients had the lowest risk. This knowledge may guide clinicians in their decisions on whether to offer OTC to girls and younger women with a life‐threatening disease.This article is protected by copyright. All rights reserved.
This study was designed to determine whether breast cancer cells with stemlike properties are present in residual disease after neoadjuvant chemotherapy and whether they exhibit oncogenic mutations. The presence of breast cancer cells with stemlike properties with specific mutations may help explain the poor prognosis associated with residual disease.
Skin toxicity is a common problem not only when treating breast cancer but in all cancer types. Visible on the surface, these side effects come not just with burdening symptoms but also with stigmatization. With increasing diversity in therapeutic options, dermatologic side effects are also becoming increasingly complex and more challenging for the clinician. We reviewed the most common dermatologic side effects of current anticancer therapy, including toxicity induced by chemotherapy, targeted therapy, and immunotherapy. In particular, we focus on xerosis and pruritus, (acneiform) exanthema, hand-foot syndrome, nail toxic...
Conclusion: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence.Breast Care
There some evidence in PubMed than medicinal mushrooms may play a role in treatment of some cancers. Most of the claims of medical benefits are bot backed up by high quality studies as of 2019. References are below.---What is turkey tail?Turkey tail is a type of mushroom that grows on dead logs worldwide. It's named turkey tail because its rings of brown and tan look like the tail feathers of a turkey. Its scientific name is Trametes versicolor or Coriolus versicolor. In traditional Chinese medicine, it is known as Yun Zhi. In Japan, it is known as kawaratake (roof tile fungus). Turkey tail has been used in traditional Chi...
ConclusionILC patients could derive significant DFS and OS benefits from CT, especially for high-risk patients.
Condition: BRCA Gene Rearrangement Interventions: Genetic: BRCA 1; Drug: Chemotherapy Sponsor: Chung-Ang University Recruiting